



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
INFORMATION DISCLOSURE STATEMENT		Docket Number: 1662/55602	
Application Number 10/045,970	Filing Date January 11, 2002	Examiner Laura Stockton	Art Unit 1626
Invention Title A Novel Process For Preparing Pure Ondansetron Hydrochloride Dihydrate		Inventors LIDOR-HADAS, et al.	

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. In accordance with the Official Gazette of August 5, 2003, which stated that the United States Patent and Trademark Office waived the requirement under 37 C.F.R. § 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
5. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.


Dated: 2-17-05

By:

Dana Ziker (Reg. No. 54,567)

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, D.C. 20005-1257
(202) 220-4200 (telephone)
(202) 220-4201 (facsimile)
CUSTOMER NO. 26646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/55602	U.S. SERIAL NO. 10/045,970
	APPLICANT(S) LIDOR-HADAS, et al.	
	FILING DATE January 11, 2002	GROUP 1626



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		U.S. Patent Application Publication, US 2005/0020655 A1, January 27, 2005, Molnar, et al.,
		The United States Pharmacopeia (USP 27-NF22), 22 nd edition, First Supplement, April, 2004, pages 3030, 3075-3076 /
		The United States Pharmacopeia (USP 27-NF22), 22 nd edition, Second Supplement, August, 2004, pages 3234, 3283-3285 ✓
		The United States Pharmacopeia (USP 26-NF21), 21 st edition, The National Formulary, January, 2003, pages 1351-1352 ✓

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

The PTO did not receive the following
 listed item(s) USP. US/2005/002065 A1, 1-27-05